Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Review Article

针对卵巢癌治疗中的六个癌症标志

卷 20, 期 11, 2020

页: [853 - 867] 页: 15

弟呕挨: 10.2174/1568009620999200816130218

价格: $65

摘要

正常细胞必须克服多种保护机制才能发展为癌细胞。它们的新功能包括生长信号的自给和对抗生长信号的不敏感性,细胞凋亡的逃避,无限的复制潜力,持续的血管生成以及组织的侵袭和转移。这些也被称为癌症的六个标志。对这些过程中涉及的遗传和蛋白质改变的深入了解,使得寻找卵巢癌治疗方法的靶向治疗策略和临床试验设计得以发展。临床上,单用PARP,MEK,VEGF和Chk1 / Chk2抑制剂可观察到更长的无进展生存期。但是,靶向药物的临床疗效仍仅限于特定的分子亚型,尚无试验表明总生存获益。探索新的药物靶标或结合当前可行的生物制剂,有望进一步改善卵巢癌的治疗效果。在这篇综述中,我们打算对涉及卵巢癌致癌作用的分子变化和新兴生物因子以及针对异常途径的联合策略进行全面描述,这可能为将来的卵巢癌治疗提供启示。

关键词: 卵巢癌,癌症标志,靶向治疗,PARP,MEK,VEGF。

图形摘要

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Wiggans, A.J.; Cass, G.K.; Bryant, A.; Lawrie, T.A.; Morrison, J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst. Rev., 2015, (5): CD007929.
[http://dx.doi.org/10.1002/14651858.CD007929.pub3] [PMID: 25991068]
[3]
Ledermann, J. A.; Raja, F. A.; Fotopoulou, C.; Gonzalez-Martin, A.; Colombo, N.; Sessa, C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2018, 29(4), iv259.
[4]
Moore, K.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; Gourley, C.; Banerjee, S.; Oza, A.; González-Martín, A.; Aghajanian, C.; Bradley, W.; Mathews, C.; Liu, J.; Lowe, E.S.; Bloomfield, R.; DiSilvestro, P. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med., 2018, 379(26), 2495-2505.
[http://dx.doi.org/10.1056/NEJMoa1810858] [PMID: 30345884]
[5]
Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
[http://dx.doi.org/10.1016/S0092-8674(00)81683-9] [PMID: 10647931]
[6]
Landen, C.N., Jr; Birrer, M.J.; Sood, A.K. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol., 2008, 26(6), 995-1005.
[http://dx.doi.org/10.1200/JCO.2006.07.9970] [PMID: 18195328]
[7]
Zeineldin, R.; Muller, C.Y.; Stack, M.S.; Hudson, L.G. Targeting the EGF receptor for ovarian cancer therapy. J. Oncol., 2010, 2010, 414676.
[http://dx.doi.org/10.1155/2010/414676] [PMID: 20066160]
[8]
Bos, J.L.; Rehmann, H.; Wittinghofer, A. GEFs and GAPs: critical elements in the control of small G proteins. Cell, 2007, 129(5), 865-877.
[http://dx.doi.org/10.1016/j.cell.2007.05.018] [PMID: 17540168]
[9]
Krengel, U.; Schlichting, I.; Scherer, A.; Schumann, R.; Frech, M.; John, J.; Kabsch, W.; Pai, E.F.; Wittinghofer, A. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell, 1990, 62(3), 539-548.
[http://dx.doi.org/10.1016/0092-8674(90)90018-A] [PMID: 2199064]
[10]
Harrington, B.S.; Annunziata, C.M. NF-κB signaling in ovarian cancer. Cancers (Basel), 2019, 11(8), E1182.
[http://dx.doi.org/10.3390/cancers11081182] [PMID: 31443240]
[11]
Appert-Collin, A.; Hubert, P.; Crémel, G.; Bennasroune, A. Role of ErbB receptors in cancer cell migration and invasion. Front. Pharmacol., 2015, 6, 283.
[http://dx.doi.org/10.3389/fphar.2015.00283] [PMID: 26635612]
[12]
Mallmann-Gottschalk, N.; Sax, Y.; Kimmig, R.; Lang, S.; Brandau, S. EGFR-specific tyrosine kinase inhibitor modifies NK cell-mediated antitumoral activity against ovarian cancer cells. Int. J. Mol. Sci., 2019, 20(19)E4693
[http://dx.doi.org/10.3390/ijms20194693] [PMID: 31546690]
[13]
Haldar, K.; Gaitskell, K.; Bryant, A.; Nicum, S.; Kehoe, S.; Morrison, J. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Cochrane Database Syst. Rev., 2011, (10)CD007927
[http://dx.doi.org/10.1002/14651858.CD007927.pub3] [PMID: 21975775]
[14]
Zhou, X.; Shi, K.; Hao, Y.; Yang, C.; Zha, R.; Yi, C.; Qian, Z. Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. Asian J Pharm Sci, 2020, 15(1), 26-41.
[http://dx.doi.org/10.1016/j.ajps.2019.06.001] [PMID: 32175016]
[15]
Domínguez-Ríos, R.; Sánchez-Ramírez, D.R.; Ruiz-Saray, K.; Oceguera-Basurto, P.E.; Almada, M.; Juárez, J.; Zepeda-Moreno, A.; Del Toro-Arreola, A.; Topete, A.; Daneri-Navarro, A. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloids Surf. B Biointerfaces, 2019, 178, 199-207.
[http://dx.doi.org/10.1016/j.colsurfb.2019.03.011] [PMID: 30856589]
[16]
Ghassami, E.; Varshosaz, J.; Minaiyan, M.; Nasirikenari, M.; Hoseini, S.M. Biodistribution, safety and organ toxicity of docetaxel-loaded in HER-2 aptamer conjugated ecoflex® nanoparticles in a mouse xenograft model of ovarian cancer. Recent Pat. Nanotechnol., 2019, 13(1), 49-58.
[http://dx.doi.org/10.2174/1872210513666181128162403] [PMID: 30488805]
[17]
Sui, H.; Shi, C.; Yan, Z.; Li, H. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Drug Des. Devel. Ther., 2015, 9, 3183-3190.
[http://dx.doi.org/10.2147/DDDT.S82035] [PMID: 26124641]
[18]
McCormick, F. KRAS as a Therapeutic Target. Clin. Cancer. Res., 2015, 21(8), 1797-801.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2662]
[19]
Christensen, J.G.; Olson, P.; Briere, T.; Wiel, C.; Bergo, M.O. Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor. J. Intern. Med., 2020, 288(2), 183-191.
[http://dx.doi.org/10.1111/joim.13057] [PMID: 32176377]
[20]
Liu, P.; Wang, Y.; Li, X. Targeting the untargetable KRAS in cancer therapy. Acta Pharm. Sin. B, 2019, 9(5), 871-879.
[http://dx.doi.org/10.1016/j.apsb.2019.03.002] [PMID: 31649840]
[21]
Husseinzadeh, N.; Husseinzadeh, H.D. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol. Oncol., 2014, 133(2), 375-381.
[http://dx.doi.org/10.1016/j.ygyno.2014.02.017] [PMID: 24556063]
[22]
Behbakht, K.; Sill, M.W.; Darcy, K.M.; Rubin, S.C.; Mannel, R.S.; Waggoner, S.; Schilder, R.J.; Cai, K.Q.; Godwin, A.K.; Alpaugh, R.K. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol. Oncol., 2011, 123(1), 19-26.
[http://dx.doi.org/10.1016/j.ygyno.2011.06.022] [PMID: 21752435]
[23]
Della Pepa, C.; Tonini, G.; Santini, D.; Losito, S.; Pisano, C.; Di Napoli, M.; Cecere, S.C.; Gargiulo, P.; Pignata, S. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat. Rev., 2015, 41(2), 136-143.
[http://dx.doi.org/10.1016/j.ctrv.2014.12.003] [PMID: 25573350]
[24]
Hyman, D.M.; Puzanov, I.; Subbiah, V.; Faris, J.E.; Chau, I.; Blay, J.Y.; Wolf, J.; Raje, N.S.; Diamond, E.L.; Hollebecque, A.; Gervais, R.; Elez-Fernandez, M.E.; Italiano, A.; Hofheinz, R.D.; Hidalgo, M.; Chan, E.; Schuler, M.; Lasserre, S.F.; Makrutzki, M.; Sirzen, F.; Veronese, M.L.; Tabernero, J.; Baselga, J. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N. Engl. J. Med., 2015, 373(8), 726-736.
[http://dx.doi.org/10.1056/NEJMoa1502309] [PMID: 26287849]
[25]
Farley, J.; Brady, W.E.; Vathipadiekal, V.; Lankes, H.A.; Coleman, R.; Morgan, M.A.; Mannel, R.; Yamada, S.D.; Mutch, D.; Rodgers, W.H.; Birrer, M.; Gershenson, D.M. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol., 2013, 14(2), 134-140.
[http://dx.doi.org/10.1016/S1470-2045(12)70572-7] [PMID: 23261356]
[26]
Arend, R.C.; Davis, A.M.; Chimiczewski, P.; O’Malley, D.M.; Provencher, D.; Vergote, I.; Ghamande, S.; Birrer, M.J. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. Gynecol. Oncol., 2020, 156(2), 301-307.
[http://dx.doi.org/10.1016/j.ygyno.2019.12.002] [PMID: 31870556]
[27]
Bedard, P. L.; Tabernero, J.; Janku, F.; Wainberg, Z. A.; Paz-Ares, L.; Vansteenkiste, J.; Van Cutsem, E.; Perez-Garcia, J.; Stathis, A.; Britten, C. D.; Le, N.; Carter, K.; Demanse, D.; Csonka, D.; Peters, M.; Zubel, A.; Nauwelaerts, H.; Sessa, C. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, 21(4), 730-738.
[28]
Kinross, K.M.; Brown, D.V.; Kleinschmidt, M.; Jackson, S.; Christensen, J.; Cullinane, C.; Hicks, R.J.; Johnstone, R.W.; McArthur, G.A. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Mol. Cancer Ther., 2011, 10(8), 1440-1449.
[http://dx.doi.org/10.1158/1535-7163.MCT-11-0240] [PMID: 21632463]
[29]
Wainberg, Z.A.; Alsina, M.; Soares, H.P.; Braña, I.; Britten, C.D.; Del Conte, G.; Ezeh, P.; Houk, B.; Kern, K.A.; Leong, S.; Pathan, N.; Pierce, K.J.; Siu, L.L.; Vermette, J.; Tabernero, J. A multi-arm phase I study of the PI3K/mTOR inhibitors PF-04691502 and gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in advanced cancer. Target. Oncol., 2017, 12(6), 775-785.
[http://dx.doi.org/10.1007/s11523-017-0530-5] [PMID: 29067643]
[30]
Kessler, D.; Gmachl, M.; Mantoulidis, A.; Martin, L.J.; Zoephel, A.; Mayer, M.; Gollner, A.; Covini, D.; Fischer, S.; Gerstberger, T.; Gmaschitz, T.; Goodwin, C.; Greb, P.; Häring, D.; Hela, W.; Hoffmann, J.; Karolyi-Oezguer, J.; Knesl, P.; Kornigg, S.; Koegl, M.; Kousek, R.; Lamarre, L.; Moser, F.; Munico-Martinez, S.; Peinsipp, C.; Phan, J.; Rinnenthal, J.; Sai, J.; Salamon, C.; Scherbantin, Y.; Schipany, K.; Schnitzer, R.; Schrenk, A.; Sharps, B.; Siszler, G.; Sun, Q.; Waterson, A.; Wolkerstorfer, B.; Zeeb, M.; Pearson, M.; Fesik, S.W.; McConnell, D.B. Drugging an undruggable pocket on KRAS. Proc. Natl. Acad. Sci. USA, 2019, 116(32), 15823-15829.
[http://dx.doi.org/10.1073/pnas.1904529116] [PMID: 31332011]
[31]
Canon, J.; Rex, K.; Saiki, A.Y.; Mohr, C.; Cooke, K.; Bagal, D.; Gaida, K.; Holt, T.; Knutson, C.G.; Koppada, N.; Lanman, B.A.; Werner, J.; Rapaport, A.S.; San Miguel, T.; Ortiz, R.; Osgood, T.; Sun, J-R.; Zhu, X.; McCarter, J.D.; Volak, L.P.; Houk, B.E.; Fakih, M.G.; O’Neil, B.H.; Price, T.J.; Falchook, G.S.; Desai, J.; Kuo, J.; Govindan, R.; Hong, D.S.; Ouyang, W.; Henary, H.; Arvedson, T.; Cee, V.J.; Lipford, J.R. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 2019, 575(7781), 217-223.
[http://dx.doi.org/10.1038/s41586-019-1694-1] [PMID: 31666701]
[32]
Nagasaka, M.; Li, Y.; Sukari, A.; Ou, S.I.; Al-Hallak, M.N.; Azmi, A.S. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat. Rev., 2020, 84, 101974.
[http://dx.doi.org/10.1016/j.ctrv.2020.101974] [PMID: 32014824]
[33]
Kim, M. J.; Lee, S. J.; Ryu, J. H.; Kim, S. H.; Kwon, I. C.; Roberts, T. M. Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment J. Control. Release, 2020, 318, 98-108.
[34]
Chen, J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb. Perspect. Med., 2016, 6(3), a026104.
[http://dx.doi.org/10.1101/cshperspect.a026104] [PMID: 26931810]
[35]
Skilling, J.S.; Sood, A.; Niemann, T.; Lager, D.J.; Buller, R.E. An abundance of p53 null mutations in ovarian carcinoma. Oncogene, 1996, 13(1), 117-123.
[PMID: 8700537]
[36]
Gurpinar, E.; Vousden, K.H. Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation. Trends Cell Biol., 2015, 25(8), 486-495.
[http://dx.doi.org/10.1016/j.tcb.2015.04.001] [PMID: 25960041]
[37]
Brown, J.S.; O’Carrigan, B.; Jackson, S.P.; Yap, T.A. Targeting DNA repair in cancer: Beyond PARP inhibitors. Cancer Discov., 2017, 7(1), 20-37.
[http://dx.doi.org/10.1158/2159-8290.CD-16-0860] [PMID: 28003236]
[38]
Guy, H.; Walder, L.; Fisher, M. Cost-effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of patients with ovarian cancer in the United States. Pharmacoeconomics, 2019, 37(3), 391-405.
[http://dx.doi.org/10.1007/s40273-018-0745-z] [PMID: 30478649]
[39]
Mirza, M.R.; Monk, B.J.; Herrstedt, J.; Oza, A.M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J.A.; Lorusso, D.; Vergote, I.; Ben-Baruch, N.E.; Marth, C.; Mądry, R.; Christensen, R.D.; Berek, J.S.; Dørum, A.; Tinker, A.V.; du Bois, A.; González-Martín, A.; Follana, P.; Benigno, B.; Rosenberg, P.; Gilbert, L.; Rimel, B.J.; Buscema, J.; Balser, J.P.; Agarwal, S.; Matulonis, U.A. ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med., 2016, 375(22), 2154-2164.
[http://dx.doi.org/10.1056/NEJMoa1611310] [PMID: 27717299]
[40]
Pujade-Lauraine, E.; Ledermann, J.A.; Selle, F.; Gebski, V.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Poveda, A.; Pignata, S.; Friedlander, M.; Colombo, N.; Harter, P.; Fujiwara, K.; Ray-Coquard, I.; Banerjee, S.; Liu, J.; Lowe, E.S.; Bloomfield, R.; Pautier, P. SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol., 2017, 18(9), 1274-1284.
[http://dx.doi.org/10.1016/S1470-2045(17)30469-2] [PMID: 28754483]
[41]
Swisher, E.M.; Lin, K.K.; Oza, A.M.; Scott, C.L.; Giordano, H.; Sun, J.; Konecny, G.E.; Coleman, R.L.; Tinker, A.V.; O’Malley, D.M.; Kristeleit, R.S.; Ma, L.; Bell-McGuinn, K.M.; Brenton, J.D.; Cragun, J.M.; Oaknin, A.; Ray-Coquard, I.; Harrell, M.I.; Mann, E.; Kaufmann, S.H.; Floquet, A.; Leary, A.; Harding, T.C.; Goble, S.; Maloney, L.; Isaacson, J.; Allen, A.R.; Rolfe, L.; Yelensky, R.; Raponi, M.; McNeish, I.A. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol., 2017, 18(1), 75-87.
[http://dx.doi.org/10.1016/S1470-2045(16)30559-9] [PMID: 27908594]
[42]
Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.L.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Fielding, A.; Spencer, S.; Dougherty, B.; Orr, M.; Hodgson, D.; Barrett, J.C.; Matulonis, U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol., 2014, 15(8), 852-861.
[http://dx.doi.org/10.1016/S1470-2045(14)70228-1] [PMID: 24882434]
[43]
LoRusso, P. M.; Li, J.; Burger, A.; Heilbrun, L. K.; Sausville, E. A.; Boerner, S. A.; Smith, D.; Pilat, M. J.; Zhang, J.; Tolaney, S. M.; Cleary, J. M.; Chen, A. P.; Rubinstein, L.; Boerner, J. L.; Bowditch, A.; Cai, D.; Bell, T.; Wolanski, A.; Marrero, A. M.; Zhang, Y.; Ji, J.; Ferry-Galow, K.; Kinders, R. J.; Parchment, R. E.; Shapiro, G. I.; Phase, I Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors Clin. Cancer. Res., 2016, 22(13), 3227-3237.
[44]
Oza, A.M.; Cibula, D.; Benzaquen, A.O.; Poole, C.; Mathijssen, R.H.J.; Sonke, G.S.; Colombo, N.; Špaček, J.; Vuylsteke, P.; Hirte, H.; Mahner, S.; Plante, M.; Schmalfeldt, B.; Mackay, H.; Rowbottom, J.; Lowe, E.S.; Dougherty, B.; Barrett, J.C.; Friedlander, M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol., 2015, 16(1), 87-97.
[http://dx.doi.org/10.1016/S1470-2045(14)71135-0] [PMID: 25481791]
[45]
Kummar, S.; Oza, A. M.; Fleming, G. F.; Sullivan, D. M.; Gandara, D. R.; Naughton, M. J.; Villalona-Calero, M. A.; Morgan, R. J., Jr; Szabo, P. M.; Youn, A.; Chen, A. P.; Ji, J.; Allen, D. E.; Lih, C. J.; Mehaffey, M. G.; Walsh, W. D.; McGregor, P. M., 3rd; Steinberg, S. M.; Williams, P. M.; Kinders, R. J.; Conley, B. A.; Simon, R. M.; Doroshow, J. H. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin. Cancer. Res., 2015, 21(7), 1574-1582.
[46]
González-Martín, A.; Pothuri, B.; Vergote, I.; DePont Christensen, R.; Graybill, W.; Mirza, M.R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; Baumann, K.; Jardon, K.; Redondo, A.; Moore, R.G.; Vulsteke, C.; O’Cearbhaill, R.E.; Lund, B.; Backes, F.; Barretina-Ginesta, P.; Haggerty, A.F.; Rubio-Pérez, M.J.; Shahin, M.S.; Mangili, G.; Bradley, W.H.; Bruchim, I.; Sun, K.; Malinowska, I.A.; Li, Y.; Gupta, D.; Monk, B.J. PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2391-2402.
[http://dx.doi.org/10.1056/NEJMoa1910962] [PMID: 31562799]
[47]
Coleman, R.L.; Fleming, G.F.; Brady, M.F.; Swisher, E.M.; Steffensen, K.D.; Friedlander, M.; Okamoto, A.; Moore, K.N.; Efrat Ben-Baruch, N.; Werner, T.L.; Cloven, N.G.; Oaknin, A.; DiSilvestro, P.A.; Morgan, M.A.; Nam, J.H.; Leath, C.A., III; Nicum, S.; Hagemann, A.R.; Littell, R.D.; Cella, D.; Baron-Hay, S.; Garcia-Donas, J.; Mizuno, M.; Bell-McGuinn, K.; Sullivan, D.M.; Bach, B.A.; Bhattacharya, S.; Ratajczak, C.K.; Ansell, P.J.; Dinh, M.H.; Aghajanian, C.; Bookman, M.A. Veliparib with first-line cChemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2403-2415.
[http://dx.doi.org/10.1056/NEJMoa1909707] [PMID: 31562800]
[48]
Thomas, A.; Redon, C.E.; Sciuto, L.; Padiernos, E.; Ji, J.; Lee, M-J.; Yuno, A.; Lee, S.; Zhang, Y.; Tran, L.; Yutzy, W.; Rajan, A.; Guha, U.; Chen, H.; Hassan, R.; Alewine, C.C.; Szabo, E.; Bates, S.E.; Kinders, R.J.; Steinberg, S.M.; Doroshow, J.H.; Aladjem, M.I.; Trepel, J.B.; Pommier, Y.; Phase, I. Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J. Clin. Oncol., 2018, 36(16), 1594-1602.
[http://dx.doi.org/10.1200/JCO.2017.76.6915] [PMID: 29252124]
[49]
Bradbury, A.; Hall, S.; Curtin, N.; Drew, Y. Targeting ATR as cancer therapy: A new era for synthetic lethality and synergistic combinations? Pharmacol. Ther., 2020, 207107450
[http://dx.doi.org/10.1016/j.pharmthera.2019.107450] [PMID: 31836456]
[50]
Lee, J-M.; Nair, J.; Zimmer, A.; Lipkowitz, S.; Annunziata, C.M.; Merino, M.J.; Swisher, E.M.; Harrell, M.I.; Trepel, J.B.; Lee, M-J.; Bagheri, M.H.; Botesteanu, D-A.; Steinberg, S.M.; Minasian, L.; Ekwede, I.; Kohn, E.C. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol., 2018, 19(2), 207-215.
[http://dx.doi.org/10.1016/S1470-2045(18)30009-3] [PMID: 29361470]
[51]
Ivy, S.P.; Kunos, C.A.; Arnaldez, F.I.; Kohn, E.C. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. Expert Opin. Investig. Drugs, 2019, 28(9), 771-785.
[http://dx.doi.org/10.1080/13543784.2019.1657403] [PMID: 31449760]
[52]
Reinhardt, H.C.; Aslanian, A.S.; Lees, J.A.; Yaffe, M.B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 2007, 11(2), 175-189.
[http://dx.doi.org/10.1016/j.ccr.2006.11.024] [PMID: 17292828]
[53]
Reinhardt, H.C.; Hasskamp, P.; Schmedding, I.; Morandell, S.; van Vugt, M.A.; Wang, X.; Linding, R.; Ong, S.E.; Weaver, D.; Carr, S.A.; Yaffe, M.B. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol. Cell, 2010, 40(1), 34-49.
[http://dx.doi.org/10.1016/j.molcel.2010.09.018] [PMID: 20932473]
[54]
Morandell, S.; Reinhardt, H.C.; Cannell, I.G.; Kim, J.S.; Ruf, D.M.; Mitra, T.; Couvillon, A.D.; Jacks, T.; Yaffe, M.B. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep., 2013, 5(4), 868-877.
[http://dx.doi.org/10.1016/j.celrep.2013.10.025] [PMID: 24239348]
[55]
Phoa, A.F.; Recasens, A.; Gurgis, F.M.S.; Betts, T.A.; Menezes, S.V.; Chau, D.; Nordfors, K.; Haapasalo, J.; Haapasalo, H.; Johns, T.G.; Stringer, B.W.; Day, B.W.; Buckland, M.E.; Lalaoui, N.; Munoz, L. MK2 inhibition induces p53-dependent senescence in glioblastoma cells. Cancers (Basel), 2020, 12(3)E654
[http://dx.doi.org/10.3390/cancers12030654] [PMID: 32168910]
[56]
Hombach, A.; Köhler, H.; Rappl, G.; Abken, H. Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J. Immunol., 2006, 177(8), 5668-5675.
[http://dx.doi.org/10.4049/jimmunol.177.8.5668] [PMID: 17015756]
[57]
Jindal, V.; Arora, E.; Gupta, S.; Lal, A.; Masab, M.; Potdar, R. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer. Med. Oncol., 2018, 35(5), 70.
[http://dx.doi.org/10.1007/s12032-018-1131-6] [PMID: 29651744]
[58]
Tanyi, J. L.; Haas, A. R.; Beatty, G. L.; Stashwick, C. J.; O'Hara, M. H.; Morgan, M. A.; Porter, D. L.; Melenhorst, J. J.; Plesa, G.; Lacey, S. F.; June, C. H. Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer Journal of Clinical Oncology, 2016, 34(15), 5511-5511.
[http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5511]
[59]
González-Martín, A.; Sánchez-Lorenzo, L. Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising? Cancer, 2019, 125(Suppl. 24), 4616-4622.
[http://dx.doi.org/10.1002/cncr.32520] [PMID: 31967676]
[60]
Lee, E.K.; Konstantinopoulos, P.A. Combined PARP and immune checkpoint inhibition in ovarian cancer. Trends Cancer, 2019, 5(9), 524-528.
[http://dx.doi.org/10.1016/j.trecan.2019.06.004] [PMID: 31474356]
[61]
Ding, L.; Kim, H.J.; Wang, Q.; Kearns, M.; Jiang, T.; Ohlson, C.E.; Li, B.B.; Xie, S.; Liu, J.F.; Stover, E.H.; Howitt, B.E.; Bronson, R.T.; Lazo, S.; Roberts, T.M.; Freeman, G.J.; Konstantinopoulos, P.A.; Matulonis, U.A.; Zhao, J.J. PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer. Cell Rep., 2018, 25(11), 2972-2980.e5.
[http://dx.doi.org/10.1016/j.celrep.2018.11.054] [PMID: 30540933]
[62]
Konstantinopoulos, P.A.; Waggoner, S.; Vidal, G.A.; Mita, M.; Moroney, J.W.; Holloway, R.; Van Le, L.; Sachdev, J.C.; Chapman-Davis, E.; Colon-Otero, G.; Penson, R.T.; Matulonis, U.A.; Kim, Y.B.; Moore, K.N.; Swisher, E.M.; Färkkilä, A.; D’Andrea, A.; Stringer-Reasor, E.; Wang, J.; Buerstatte, N.; Arora, S.; Graham, J.R.; Bobilev, D.; Dezube, B.J.; Munster, P. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol., 2019.
[http://dx.doi.org/10.1001/jamaoncol.2019.1048] [PMID: 31194228]
[63]
Spring, L.M.; Wander, S.A.; Andre, F.; Moy, B.; Turner, N.C.; Bardia, A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet, 2020, 395(10226), 817-827.
[http://dx.doi.org/10.1016/S0140-6736(20)30165-3] [PMID: 32145796]
[64]
Konecny, G.E. Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer. EBioMedicine, 2019, 43, 9-10.
[http://dx.doi.org/10.1016/j.ebiom.2019.04.009] [PMID: 30979685]
[65]
Maoz, A.; Ciccone, M.A.; Matsuzaki, S.; Coleman, R.L.; Matsuo, K. Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opin. Emerg. Drugs, 2019, 24(4), 239-253.
[http://dx.doi.org/10.1080/14728214.2019.1696773] [PMID: 31755325]
[66]
Do, K.; Wilsker, D.; Ji, J.; Zlott, J.; Freshwater, T.; Kinders, R.J.; Collins, J.; Chen, A.P.; Doroshow, J.H.; Kummar, S.; Phase, I. Phase I study of single-agent AZD1775 (MK-1775), a wee1 kinase inhibitor, in patients with refractory solid tumors. J. Clin. Oncol., 2015, 33(30), 3409-3415.
[http://dx.doi.org/10.1200/JCO.2014.60.4009] [PMID: 25964244]
[67]
Luo, Y.; Yi, Y.; Yao, Z. Growth arrest in ovarian cancer cells by hTERT inhibition short-hairpin RNA targeting human telomerase reverse transcriptase induces immediate growth inhibition but not necessarily induces apoptosis in ovarian cancer cells. Cancer Invest., 2009, 27(10), 960-970.
[http://dx.doi.org/10.3109/07357900802491451] [PMID: 19909010]
[68]
Xie, X.; Hsu, J.L.; Choi, M-G.; Xia, W.; Yamaguchi, H.; Chen, C-T.; Trinh, B.Q.; Lu, Z.; Ueno, N.T.; Wolf, J.K.; Bast, R.C., Jr; Hung, M-C. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol. Cancer Ther., 2009, 8(8), 2375-2382.
[http://dx.doi.org/10.1158/1535-7163.MCT-09-0056] [PMID: 19671744]
[69]
Takakura, M.; Nakamura, M.; Kyo, S.; Hashimoto, M.; Mori, N.; Ikoma, T.; Mizumoto, Y.; Fujiwara, T.; Urata, Y.; Inoue, M. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther., 2010, 17(1), 11-19.
[http://dx.doi.org/10.1038/cgt.2009.44] [PMID: 19662088]
[70]
Burger, R.A.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Monk, B.J.; Huang, H.; Mannel, R.S.; Homesley, H.D.; Fowler, J.; Greer, B.E.; Boente, M.; Birrer, M.J.; Liang, S.X. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med., 2011, 365(26), 2473-2483.
[http://dx.doi.org/10.1056/NEJMoa1104390] [PMID: 22204724]
[71]
Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C.; du Bois, A.; Sehouli, J.; Kimmig, R.; Stähle, A.; Collinson, F.; Essapen, S.; Gourley, C.; Lortholary, A.; Selle, F.; Mirza, M.R.; Leminen, A.; Plante, M.; Stark, D.; Qian, W.; Parmar, M.K.B.; Oza, A.M. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med., 2011, 365(26), 2484-2496.
[http://dx.doi.org/10.1056/NEJMoa1103799] [PMID: 22204725]
[72]
Aghajanian, C.; Blank, S.V.; Goff, B.A.; Judson, P.L.; Teneriello, M.G.; Husain, A.; Sovak, M.A.; Yi, J.; Nycum, L.R. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol., 2012, 30(17), 2039-2045.
[http://dx.doi.org/10.1200/JCO.2012.42.0505] [PMID: 22529265]
[73]
Pujade-Lauraine, E.; Hilpert, F.; Weber, B.; Reuss, A.; Poveda, A.; Kristensen, G.; Sorio, R.; Vergote, I.; Witteveen, P.; Bamias, A.; Pereira, D.; Wimberger, P.; Oaknin, A.; Mirza, M.R.; Follana, P.; Bollag, D.; Ray-Coquard, I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol., 2014, 32(13), 1302-1308.
[http://dx.doi.org/10.1200/JCO.2013.51.4489] [PMID: 24637997]
[74]
du Bois, A.; Floquet, A.; Kim, J.W.; Rau, J.; del Campo, J.M.; Friedlander, M.; Pignata, S.; Fujiwara, K.; Vergote, I.; Colombo, N.; Mirza, M.R.; Monk, B.J.; Kimmig, R.; Ray-Coquard, I.; Zang, R.; Diaz-Padilla, I.; Baumann, K.H.; Mouret-Reynier, M.A.; Kim, J.H.; Kurzeder, C.; Lesoin, A.; Vasey, P.; Marth, C.; Canzler, U.; Scambia, G.; Shimada, M.; Calvert, P.; Pujade-Lauraine, E.; Kim, B.G.; Herzog, T.J.; Mitrica, I.; Schade-Brittinger, C.; Wang, Q.; Crescenzo, R.; Harter, P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J. Clin. Oncol., 2014, 32(30), 3374-3382.
[http://dx.doi.org/10.1200/JCO.2014.55.7348] [PMID: 25225436]
[75]
du Bois, A.; Kristensen, G.; Ray-Coquard, I.; Reuss, A.; Pignata, S.; Colombo, N.; Denison, U.; Vergote, I.; Del Campo, J.M.; Ottevanger, P.; Heubner, M.; Minarik, T.; Sevin, E.; de Gregorio, N.; Bidziński, M.; Pfisterer, J.; Malander, S.; Hilpert, F.; Mirza, M.R.; Scambia, G.; Meier, W.; Nicoletto, M.O.; Bjørge, L.; Lortholary, A.; Sailer, M.O.; Merger, M.; Harter, P. AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol., 2016, 17(1), 78-89.
[http://dx.doi.org/10.1016/S1470-2045(15)00366-6] [PMID: 26590673]
[76]
Ledermann, J.A.; Hackshaw, A.; Kaye, S.; Jayson, G.; Gabra, H.; McNeish, I.; Earl, H.; Perren, T.; Gore, M.; Persic, M.; Adams, M.; James, L.; Temple, G.; Merger, M.; Rustin, G. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J. Clin. Oncol., 2011, 29(28), 3798-3804.
[http://dx.doi.org/10.1200/JCO.2010.33.5208] [PMID: 21859991]
[77]
Ledermann, J.A.; Embleton, A.C.; Raja, F.; Perren, T.J.; Jayson, G.C.; Rustin, G.J.S.; Kaye, S.B.; Hirte, H.; Eisenhauer, E.; Vaughan, M.; Friedlander, M.; González-Martín, A.; Stark, D.; Clark, E.; Farrelly, L.; Swart, A.M.; Cook, A.; Kaplan, R.S.; Parmar, M.K.B. ICON6 collaborators. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2016, 387(10023), 1066-1074.
[http://dx.doi.org/10.1016/S0140-6736(15)01167-8] [PMID: 27025186]
[78]
Pignata, S.; Lorusso, D.; Scambia, G.; Sambataro, D.; Tamberi, S.; Cinieri, S.; Mosconi, A.M.; Orditura, M.; Brandes, A.A.; Arcangeli, V.; Panici, P.B.; Pisano, C.; Cecere, S.C.; Di Napoli, M.; Raspagliesi, F.; Maltese, G.; Salutari, V.; Ricci, C.; Daniele, G.; Piccirillo, M.C.; Di Maio, M.; Gallo, C.; Perrone, F. MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol., 2015, 16(5), 561-568.
[http://dx.doi.org/10.1016/S1470-2045(15)70115-4] [PMID: 25882986]
[79]
Herzog, T.J.; Scambia, G.; Kim, B.G.; Lhommé, C.; Markowska, J.; Ray-Coquard, I.; Sehouli, J.; Colombo, N.; Shan, M.; Petrenciuc, O.; Oza, A. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol. Oncol., 2013, 130(1), 25-30.
[http://dx.doi.org/10.1016/j.ygyno.2013.04.011] [PMID: 23591401]
[80]
Monk, B.J.; Poveda, A.; Vergote, I.; Raspagliesi, F.; Fujiwara, K.; Bae, D.S.; Oaknin, A.; Ray-Coquard, I.; Provencher, D.M.; Karlan, B.Y.; Lhommé, C.; Richardson, G.; Rincón, D.G.; Coleman, R.L.; Herzog, T.J.; Marth, C.; Brize, A.; Fabbro, M.; Redondo, A.; Bamias, A.; Tassoudji, M.; Navale, L.; Warner, D.J.; Oza, A.M. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol., 2014, 15(8), 799-808.
[http://dx.doi.org/10.1016/S1470-2045(14)70244-X] [PMID: 24950985]
[81]
Karlan, B.Y.; Oza, A.M.; Richardson, G.E.; Provencher, D.M.; Hansen, V.L.; Buck, M.; Chambers, S.K.; Ghatage, P.; Pippitt, C.H., Jr; Brown, J.V., III; Covens, A.; Nagarkar, R.V.; Davy, M.; Leath, C.A., III; Nguyen, H.; Stepan, D.E.; Weinreich, D.M.; Tassoudji, M.; Sun, Y.N.; Vergote, I.B. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J. Clin. Oncol., 2012, 30(4), 362-371.
[http://dx.doi.org/10.1200/JCO.2010.34.3178] [PMID: 22184370]
[82]
Li, X.; Zhu, S.; Hong, C.; Cai, H. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials. Curr. Med. Res. Opin., 2016, 32(3), 555-562.
[http://dx.doi.org/10.1185/03007995.2015.1131152] [PMID: 26652645]
[83]
Liu, M.C.; Tewari, K.S. Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. Drugs Context, 2018, 7212558
[http://dx.doi.org/10.7573/dic.212558] [PMID: 30627206]
[84]
Ray-Coquard, I.; Pautier, P.; Pignata, S.; Pérol, D.; González-Martín, A.; Berger, R.; Fujiwara, K.; Vergote, I.; Colombo, N.; Mäenpää, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Guerra Alía, E.M.; Reinthaller, A.; Nagao, S.; Lefeuvre-Plesse, C.; Canzler, U.; Scambia, G.; Lortholary, A.; Marmé, F.; Combe, P.; de Gregorio, N.; Rodrigues, M.; Buderath, P.; Dubot, C.; Burges, A.; You, B.; Pujade-Lauraine, E.; Harter, P. PAOLA-1 Investigators. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2416-2428.
[http://dx.doi.org/10.1056/NEJMoa1911361] [PMID: 31851799]
[85]
Gale, N.W.; Holland, S.J.; Valenzuela, D.M.; Flenniken, A.; Pan, L.; Ryan, T.E.; Henkemeyer, M.; Strebhardt, K.; Hirai, H.; Wilkinson, D.G.; Pawson, T.; Davis, S.; Yancopoulos, G.D. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron, 1996, 17(1), 9-19.
[http://dx.doi.org/10.1016/S0896-6273(00)80276-7] [PMID: 8755474]
[86]
Landen, C.N., Jr; Lu, C.; Han, L.Y.; Coffman, K.T.; Bruckheimer, E.; Halder, J.; Mangala, L.S.; Merritt, W.M.; Lin, Y.G.; Gao, C.; Schmandt, R.; Kamat, A.A.; Li, Y.; Thaker, P.; Gershenson, D.M.; Parikh, N.U.; Gallick, G.E.; Kinch, M.S.; Sood, A.K. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J. Natl. Cancer Inst., 2006, 98(21), 1558-1570.
[http://dx.doi.org/10.1093/jnci/djj414] [PMID: 17077358]
[87]
Landen, C.N.; Kinch, M.S.; Sood, A.K. EphA2 as a target for ovarian cancer therapy. Expert Opin. Ther. Targets, 2005, 9(6), 1179-1187.
[http://dx.doi.org/10.1517/14728222.9.6.1179] [PMID: 16300469]
[88]
Levanon, K.; Crum, C.; Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol., 2008, 26(32), 5284-5293.
[http://dx.doi.org/10.1200/JCO.2008.18.1107] [PMID: 18854563]
[89]
Kobayashi, M.; Sawada, K.; Kimura, T. Potential of integrin inhibitors for treating ovarian cancer: A literature review. Cancers (Basel), 2017, 9(7), E83.
[http://dx.doi.org/10.3390/cancers9070083] [PMID: 28698469]
[90]
Sawada, K.; Mitra, A.K.; Radjabi, A.R.; Bhaskar, V.; Kistner, E.O.; Tretiakova, M.; Jagadeeswaran, S.; Montag, A.; Becker, A.; Kenny, H.A.; Peter, M.E.; Ramakrishnan, V.; Yamada, S.D.; Lengyel, E. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res., 2008, 68(7), 2329-2339.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-5167] [PMID: 18381440]
[91]
Bell-McGuinn, K.M.; Matthews, C.M.; Ho, S.N.; Barve, M.; Gilbert, L.; Penson, R.T.; Lengyel, E.; Palaparthy, R.; Gilder, K.; Vassos, A.; McAuliffe, W.; Weymer, S.; Barton, J.; Schilder, R.J. A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol. Oncol., 2011, 121(2), 273-279.
[http://dx.doi.org/10.1016/j.ygyno.2010.12.362] [PMID: 21276608]
[92]
Stone, R.L.; Baggerly, K.A.; Armaiz-Pena, G.N.; Kang, Y.; Sanguino, A.M.; Thanapprapasr, D.; Dalton, H.J.; Bottsford-Miller, J.; Zand, B.; Akbani, R.; Diao, L.; Nick, A.M.; DeGeest, K.; Lopez-Berestein, G.; Coleman, R.L.; Lutgendorf, S.; Sood, A.K. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol. Ther., 2014, 15(7), 919-929.
[http://dx.doi.org/10.4161/cbt.28882] [PMID: 24755674]
[93]
Golubovskaya, V.M.; Nyberg, C.; Zheng, M.; Kweh, F.; Magis, A.; Ostrov, D.; Cance, W.G. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J. Med. Chem., 2008, 51(23), 7405-7416.
[http://dx.doi.org/10.1021/jm800483v] [PMID: 18989950]
[94]
Halder, J.; Lin, Y.G.; Merritt, W.M.; Spannuth, W.A.; Nick, A.M.; Honda, T.; Kamat, A.A.; Han, L.Y.; Kim, T.J.; Lu, C.; Tari, A.M.; Bornmann, W.; Fernandez, A.; Lopez-Berestein, G.; Sood, A.K. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res., 2007, 67(22), 10976-10983.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-2667] [PMID: 18006843]
[95]
Shahzad, M.M.; Lu, C.; Lee, J.W.; Stone, R.L.; Mitra, R.; Mangala, L.S.; Lu, Y.; Baggerly, K.A.; Danes, C.G.; Nick, A.M.; Halder, J.; Kim, H.S.; Vivas-Mejia, P.; Landen, C.N.; Lopez-Berestein, G.; Coleman, R.L.; Sood, A.K. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol. Ther., 2009, 8(11), 1027-1034.
[http://dx.doi.org/10.4161/cbt.8.11.8523] [PMID: 19395869]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy
Request history8.2.27PHP Version438msRequest Duration28MBMemory UsageGET article/{article_id}/{param?}Route
  • warninglog[18:11:45] LOG.warning: Optional parameter $article_id declared before required parameter $request i...
  • warninglog[18:11:45] LOG.warning: trim(): Passing null to parameter #1 ($string) of type string is deprecated ...
  • warninglog[18:11:45] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • Booting (137ms)time
  • Application (300ms)time
  • 1 x Application (68.6%)
    300ms
    1 x Booting (31.39%)
    137ms
    14 templates were rendered
    • articlearticle.blade.php#?blade
    • includes.article_top_bannerarticle_top_banner.blade.php#?blade
    • includes.article_referencearticle_reference.blade.php#?blade
    • export_citation_formexport_citation_form.blade.php#?blade
    • includes.article_bottom_bannerarticle_bottom_banner.blade.php#?blade
    • includes.inc_related_journalsinc_related_journals.blade.php#?blade
    • includes.inc_related_ebooksinc_related_ebooks.blade.php#?blade
    • includes.journal_rightmenujournal_rightmenu.blade.php#?blade
    • includes.journal_right_bannerjournal_right_banner.blade.php#?blade
    • layouts.appapp.blade.php#?blade
    • layouts._login_access_login_access.blade.php#?blade
    • layouts._header_header.blade.php#?blade
    • layouts._main_menu_main_menu.blade.php#?blade
    • layouts._footer_menu_footer_menu.blade.php#?blade
    uri
    GET article/{article_id}/{param?}
    middleware
    web, check_user_access
    controller
    App\Http\Controllers\ArticleController@GetArticleDetails
    namespace
    App\Http\Controllers
    where
    as
    article
    file
    app/Http/Controllers/ArticleController.php:1974-2510
    41 statements were executed, 4 of which were duplicates, 37 unique. Show only duplicated204ms
    • Connection Establishedalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 9. middleware::check_user_access:24
      • 10. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 11. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address (ip_address,visitor_agent,visitor_count, created_on,updated_on) VALUES ('314567762','',1,1739988705,1739988705) ON DUPLICATE KEY UPDATE visitor_count=visitor_count + 1, updated_on=1739988705
      1.1msalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 11. middleware::check_user_access:24
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address_detail (ip_address,visitor_url,visitor_count, created_on,updated_on) VALUES ('314567762','/article/109125/cn',1,1739988705,1739988705)
      160μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#27
      Backtrace
      • 11. middleware::check_user_access:27
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_trail WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_corporate WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_token WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_trail WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_corporate WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_token WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_trail WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_corporate WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_token WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_trail WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_corporate WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_token WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_trail WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_corporate WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_token WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_disease_corporate WHERE to_ip >= 314567762 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314567762) limit 1
      14.08msalphaeurekaselec_live_10_06_2022UserAccess.php#784
      Bindings
      • 0: 314567762
      • 1: 314567762
      • 2: 314567762
      • 3: 314567762
      • 4: 314567762
      • 5: 314567762
      • 6: 314567762
      • 7: 314567762
      • 8: 314567762
      • 9: 314567762
      • 10: 314567762
      • 11: 314567762
      • 12: 314567762
      • 13: 314567762
      • 14: 314567762
      • 15: 314567762
      Backtrace
      • 14. app/Models/UserAccess/UserAccess.php:784
      • 15. middleware::check_user_access:114
      • 16. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 18. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
    • SELECT at.type_name, p.copyright, p.publisher_location,m.month,y.year, a.publish_on, a.nid article_nid,a.article_id, a.pmid, a.issue_id, a.title, a.abstract,a.podcast,a.altmetric_score,a.altmetric_url,a.kudos_url, a.page_count, a.first_page, a.elocator, a.last_page, i.publication_date, a.file_name, a.file_path, a.doi, a.is_epub,a.epub_type, a.volume_id, a.is_uploaded, a.editor_choice, a.is_epub, j.image_file_name, a.article_no, a.art_type AS article_type, a.supplementary_filename,a.html_filename,a.prc_filename,a.epub_filename, a.graph_abs_lg_filename, a.graph_abs_sm_filename, a.oa_image_lg_filename, a.oa_image_sm_filename, j.journal_banner,a.animated_abstract,a.erratum_in,a.erratum_for, (CASE WHEN a.issue_id =0 THEN j.epub_price ELSE j.price END) AS sell_price, j.epub_price, j.nid AS jour_nid, j.title AS journal_title, j.issn, j.eissn,j.journal_id, j.subtitle AS jour_subtitle, v.volume_id,v.volume_name AS volume, v.year_id, i.title AS issue, i.month_id ,i.type issue_type, j.subtitle,j.formerly_title, ac.subtitle AS epub_title,a.crossmark_enabled,a.text_mining_urls,a.license_urls,a.created, a.receivedate, a.revisedate, a.acceptdate,js.js_title FROM article a LEFT JOIN article_section ac ON a.is_epub = ac.art_sec_id LEFT JOIN journal_section js ON a.js_id = js.js_id LEFT JOIN article_type at ON a.art_type = at.art_type_id LEFT JOIN issue i ON a.issue_id = i.issue_id LEFT JOIN month m ON m.id = i.month_id LEFT JOIN volume v ON v.volume_id = a.volume_id INNER JOIN year y ON y.id = v.year_id INNER JOIN journal j ON j.journal_id = a.journal_id INNER JOIN publisher p ON p.publisher_id = j.publisher_id WHERE a.article_id=109125
      740μsalphaeurekaselec_live_10_06_2022Article.php#408
      Backtrace
      • 11. app/Models/Article.php:408
      • 12. app/Http/Controllers/ArticleController.php:2515
      • 13. app/Http/Controllers/ArticleController.php:2035
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `journal` where `journal_id` = 7 limit 1
      890μsalphaeurekaselec_live_10_06_2022Journal.php#64
      Bindings
      • 0: 7
      Backtrace
      • 14. app/Models/Journal.php:64
      • 15. app/Http/Controllers/ArticleController.php:2516
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=7) and sj.journal_id!=7 group by `j`.`nid`) as `aggregate_table`
      1.53msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 16. app/Models/Subject.php:200
      • 17. app/Http/Controllers/ArticleController.php:2517
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=7) and sj.journal_id!=7 group by `j`.`nid` order by `j`.`journal_id` asc limit 10 offset 0
      1.22msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 14. app/Models/Subject.php:200
      • 15. app/Http/Controllers/ArticleController.php:2517
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=7) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid`) as `aggregate_table`
      2.33msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 16. app/Models/Subject.php:220
      • 17. app/Http/Controllers/ArticleController.php:2518
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=7) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid` order by `v`.`ebook_volume_id` desc limit 10 offset 0
      2.08msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 14. app/Models/Subject.php:220
      • 15. app/Http/Controllers/ArticleController.php:2518
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `keywords` where `article_id` = '109125'
      1.25msalphaeurekaselec_live_10_06_2022Keywords.php#43
      Bindings
      • 0: 109125
      Backtrace
      • 13. app/Models/Keywords.php:43
      • 14. app/Http/Controllers/ArticleController.php:2519
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `article_citation` where `article_id` = '109125'
      5.06msalphaeurekaselec_live_10_06_2022Article.php#1570
      Bindings
      • 0: 109125
      Backtrace
      • 13. app/Models/Article.php:1570
      • 14. app/Http/Controllers/ArticleController.php:2520
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT(au.last_name, IFNULL(CONCAT(' ', au.initials), ''), ' ', au.first_name) AS authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs, CONCAT_WS(' ',au.first_name, IFNULL(CONCAT(' ', au.initials), ''), IFNULL(CONCAT(' ', au.last_name), '')) as authorsmodal , `au`.*, `af`.`ror_id`, `af`.`institution`, `af`.`department`, `af`.`country`, `af`.`city`, `af`.`address`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `author` as `au` left join `author_affiliation` as `af` on `au`.`author_id` = `af`.`author_id` where `au`.`article_id` = '109125' group by `au`.`author_id` order by `au`.`article_id` asc, `au`.`sequence` asc
      1.46msalphaeurekaselec_live_10_06_2022Author.php#86
      Bindings
      • 0: 109125
      Backtrace
      • 13. app/Models/Author.php:86
      • 14. app/Http/Controllers/ArticleController.php:2533
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      290μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2535
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `subtitle` from `journal` where `continues_publication_journal` = 1
      650μsalphaeurekaselec_live_10_06_2022Article.php#1960
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/Article.php:1960
      • 14. app/Http/Controllers/ArticleController.php:2062
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • Select j.subtitle, v.volume_id as volume_id,v.year_id,y.year as year,v.volume_name, v.total_no_of_issues, i.issue_id as issue_id,i.title as issue, i.publication_date as issue_pub_date from journal j join volume v on j.journal_id = v.journal_id join issue i on v.volume_id = i.volume_id join article a on a.issue_id = i.issue_id join year y on v.year_id = y.id where j.journal_id = 7 and i.is_uploaded = 1 order by v.volume_name+0 desc, i.title+0 desc limit 1
      29.04msalphaeurekaselec_live_10_06_2022Issue.php#298
      Backtrace
      • 11. app/Models/Issue.php:298
      • 12. app/Http/Controllers/ArticleController.php:2068
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 1 and a.journal_id = 7 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      19.86msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2070
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 4 and a.journal_id = 7 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      9.96msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2071
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select pdf, html, epub, prc from `article_metrics` where `article_id` = 109125 limit 1
      230μsalphaeurekaselec_live_10_06_2022Article.php#744
      Bindings
      • 0: 109125
      Backtrace
      • 14. app/Models/Article.php:744
      • 15. app/Http/Controllers/ArticleController.php:2091
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from content_by_diseases where content_id = 109125 and content_type = 'article' order by status desc limit 1
      310μsalphaeurekaselec_live_10_06_2022Article.php#751
      Backtrace
      • 11. app/Models/Article.php:751
      • 12. app/Http/Controllers/ArticleController.php:2094
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid article_nid,a.title article_title,j.title journal_title from content_by_diseases cd inner join article a on a.article_id=cd.content_id inner join journal j on j.journal_id=a.journal_id where cd.pid = 16 and cd.sub_disease_id = 444 and content_id!=109125 and cd.content_type = 'article' order by rand() limit 20
      48.95msalphaeurekaselec_live_10_06_2022Article.php#769
      Backtrace
      • 11. app/Models/Article.php:769
      • 12. app/Http/Controllers/ArticleController.php:2098
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `node_meta` where `nid` = 184869 limit 1
      290μsalphaeurekaselec_live_10_06_2022Meta.php#30
      Bindings
      • 0: 184869
      Backtrace
      • 14. app/Models/Meta.php:30
      • 15. app/Http/Controllers/ArticleController.php:2101
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      230μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2108
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `tbl_ht_submission` as `h` where `h`.`subtitle` = 'CCDT' and (h.proposal_closing_date = 0 OR TO_DAYS(FROM_UNIXTIME(h.proposal_closing_date)) >= TO_DAYS(NOW())) order by `h`.`manuscript` asc
      320μsalphaeurekaselec_live_10_06_2022Article.php#2025
      Bindings
      • 0: CCDT
      Backtrace
      • 13. app/Models/Article.php:2025
      • 14. app/Http/Controllers/ArticleController.php:2112
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '109125' and content_type = 'a' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      530μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2186
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '10250' and content_type = 'i' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      450μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2207
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '2791' and content_type = 'v' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      480μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2231
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314567762 and j.to_ip >=314567762 )) and ((j.from_date <= 1739988705 and j.to_date >= 1739988705 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2791) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314567762 and j.to_ip >=314567762 )) and ((j.from_date <= 1739988705 and j.to_date >= 1739988705 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2791) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314567762 and j.to_ip >=314567762 )) and ((j.from_date <= 1739988705 and j.to_date >= 1739988705 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2791)
      31.38msalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2272
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314567762 and j.to_ip >=314567762 )) and ((j.from_date <= 1739988705 and j.to_date >= 1739988705 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 10250) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314567762 and j.to_ip >=314567762 )) and ((j.from_date <= 1739988705 and j.to_date >= 1739988705 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 10250) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314567762 and j.to_ip >=314567762 )) and ((j.from_date <= 1739988705 and j.to_date >= 1739988705 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 10250)
      860μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2297
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314567762 and j.to_ip >=314567762 )) and ((j.from_date <= 1739988705 and j.to_date >= 1739988705 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 109125) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314567762 and j.to_ip >=314567762 )) and ((j.from_date <= 1739988705 and j.to_date >= 1739988705 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 109125) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314567762 and j.to_ip >=314567762 )) and ((j.from_date <= 1739988705 and j.to_date >= 1739988705 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 109125)
      900μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2329
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `first_page` < '853' and is_uploaded = 1 and issue_id = 10250 order by cast(first_page as SIGNED) desc limit 1
      650μsalphaeurekaselec_live_10_06_2022Article.php#1819
      Bindings
      • 0: 853
      Backtrace
      • 14. app/Models/Article.php:1819
      • 15. app/Http/Controllers/ArticleController.php:2470
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `last_page` > '867' and is_uploaded = 1 and issue_id = 10250 order by cast(first_page as SIGNED) asc limit 1
      540μsalphaeurekaselec_live_10_06_2022Article.php#1831
      Bindings
      • 0: 867
      Backtrace
      • 14. app/Models/Article.php:1831
      • 15. app/Http/Controllers/ArticleController.php:2472
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `language_id` from `multilanguage` where `short_code` = 'cn'
      230μsalphaeurekaselec_live_10_06_2022ArticleController.php#2486
      Bindings
      • 0: cn
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2486
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `source_lang_label`, `target_lang_label` from `multilanguage_labels` where `target_lang_id` = 2
      250μsalphaeurekaselec_live_10_06_2022MultiLanguage.php#23
      Bindings
      • 0: 2
      Backtrace
      • 13. app/Models/MultiLanguage.php:23
      • 14. app/Http/Controllers/ArticleController.php:2487
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `multilanguage_article` where (`language_id` = 2 and `article_id` = 109125)
      8.13msalphaeurekaselec_live_10_06_2022ArticleController.php#2488
      Bindings
      • 0: 2
      • 1: 109125
      Backtrace
      • 15. app/Http/Controllers/ArticleController.php:2488
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `keyword` from `multilanguage_keywords` where (`language_id` = 2 and `article_id` = 109125)
      4.53msalphaeurekaselec_live_10_06_2022ArticleController.php#2489
      Bindings
      • 0: 2
      • 1: 109125
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2489
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT_WS(' ',au.last_name, ', ', ifnull(au.initials,''), ' ', au.first_name) as authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs , `au`.*, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `multilanguage_authors` as `au` left join `multilanguage_author_affiliation` as `af` on `au`.`id` = `af`.`author_id` where `au`.`article_id` = 109125 group by `au`.`id` order by `au`.`article_id` asc, `au`.`sequence` asc
      6.67msalphaeurekaselec_live_10_06_2022MultiLangAuthor.php#30
      Bindings
      • 0: 109125
      Backtrace
      • 13. app/Models/MultiLangAuthor.php:30
      • 14. app/Http/Controllers/ArticleController.php:2493
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `multilanguage_journal`.`title` from `multilanguage_journal` where `multilanguage_journal`.`journal_id` = 7 and `language_id` = 2
      280μsalphaeurekaselec_live_10_06_2022ArticleController.php#2495
      Bindings
      • 0: 7
      • 1: 2
      Backtrace
      • 13. app/Http/Controllers/ArticleController.php:2495
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `id` from `multilanguage_article` where `article_id` = 109125 limit 1
      3.17msalphaeurekaselec_live_10_06_2022ArticleController.php#2506
      Bindings
      • 0: 109125
      Backtrace
      • 16. app/Http/Controllers/ArticleController.php:2506
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 20. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 7 and `b`.`banner_from_date` <= 1739988705 and `b`.`banner_to_date` >= 1739988705 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.16msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 7
      • 3: 1739988705
      • 4: 1739988705
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 7 and `b`.`banner_from_date` <= 1739988705 and `b`.`banner_to_date` >= 1739988705 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.1msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 7
      • 3: 1739988705
      • 4: 1739988705
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select count(*) as aggregate from `uc_cart_products` where cart_id='0a7796c4509cb24f024d6c472bc0d981'
      190μsalphaeurekaselec_live_10_06_2022Cart.php#271
      Backtrace
      • 15. app/Models/Cart.php:271
      • 16. view::layouts._header:260
      • 18. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 20. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    App\Models\MultiLangArticle
    2MultiLangArticle.php#?
    App\Models\MultiLanguage
    1MultiLanguage.php#?
        _token
        bSUpWTLBmXtrx85ab5LhX2t7EgWwc2wnj6eqTU4f
        uc_cart_id
        0a7796c4509cb24f024d6c472bc0d981
        _previous
        array:1 [ "url" => "http://alpha.eurekaselect.com/article/109125/cn" ]
        _flash
        array:2 [ "old" => [] "new" => [] ]
        PHPDEBUGBAR_STACK_DATA
        []
        path_info
        /article/109125/cn
        status_code
        200
        
        status_text
        OK
        format
        html
        content_type
        text/html; charset=UTF-8
        request_query
        []
        
        request_request
        []
        
        request_headers
        0 of 0
        array:9 [ "cookie" => array:1 [ 0 => "wayfindertarget=eyJpdiI6IlVJT0RXN01MMEdROFFvb2ZYLy9EbVE9PSIsInZhbHVlIjoibElaSXNrOGdpUmdZS2REbXFlMEtLR2N3MFJ2UExxOE5xTExyZmVoV3Q0bz0iLCJtYWMiOiJiNmFjMzE0NDczZjg4NmU3MmM0ZDY2N2E5YWE2ZmE1ZGZjMzM4MGYxMWUzMzBiMDI3Y2NkYjY3MTI4ZWIxN2E1IiwidGFnIjoiIn0%3Dwayfindertarget=eyJpdiI6IlVJT0RXN01MMEdROFFvb2ZYLy9EbVE9PSIsInZhbHVlIjoibElaSXNrOGdpUmdZS2REbXFlMEtLR2N3MFJ2UExxOE5xTExyZmVoV3Q0bz0iLCJtYWMiOiJiNmFjMzE0NDczZjg4" ] "accept-encoding" => array:1 [ 0 => "gzip, deflate" ] "accept" => array:1 [ 0 => "text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7" ] "user-agent" => array:1 [ 0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ] "upgrade-insecure-requests" => array:1 [ 0 => "1" ] "cache-control" => array:1 [ 0 => "no-cache" ] "pragma" => array:1 [ 0 => "no-cache" ] "connection" => array:1 [ 0 => "keep-alive" ] "host" => array:1 [ 0 => "alpha.eurekaselect.com" ] ]
        request_cookies
        0 of 0
        array:1 [ "wayfindertarget" => null ]
        response_headers
        0 of 0
        array:5 [ "content-type" => array:1 [ 0 => "text/html; charset=UTF-8" ] "cache-control" => array:1 [ 0 => "no-cache, private" ] "date" => array:1 [ 0 => "Wed, 19 Feb 2025 18:11:45 GMT" ] "set-cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6ImVSem1TOENldjlZSi9TSysyUWZ2ekE9PSIsInZhbHVlIjoiclk4aGQyV05pTEVISHE3eXNqUG41UFZQNHBWVCtUVTB6U3lWOU5xWmlOU2c5SFNkQjJrdmQ5emFoZi9CTWpMUHgyb3dwREdwREV2bXduRzFxdEZlTzVNbjhSTm9lbldIaU9uRk04U2pzNG9OUGowZndZcjVaMDFLM0l1bWkwRWsiLCJtYWMiOiJjNTllNjZjMDY3ZWJmZjgwNDMyN2NlNDc1MjA2ODE2ZWM2OGUzNGIzNTkyNTJkYTAwOThjYzkyYWQ3ZmZkMzI0IiwidGFnIjoiIn0%3D; expires=Sat, 22 Feb 2025 06:11:45 GMT; Max-Age=216000; path=/; secure; samesite=laxXSRF-TOKEN=eyJpdiI6ImVSem1TOENldjlZSi9TSysyUWZ2ekE9PSIsInZhbHVlIjoiclk4aGQyV05pTEVISHE3eXNqUG41UFZQNHBWVCtUVTB6U3lWOU5xWmlOU2c5SFNkQjJrdmQ5emFoZi9CTWpMUHgyb3dwR" 1 => "alphaeurekaselectnet_session=eyJpdiI6IkQ1OVRxdTJmZnRPRmJ2K2UxNEQ3bXc9PSIsInZhbHVlIjoiTWVFcWp3ZDU1R21xUG9XWk1laXZ4NDZ1UkxYb3hMQ2NINjFzVE50YjU4dkNuNkh4V3o1NVlvcHhaSGRDWU05YXNvNDlkWTIzMlJzSFJYaTVGdHA3VXdDdmFwMWV3OG16STZ4WW5tM0FLWUZGcGZoOTdXWUZ3UUYrNk5WZDl1YWgiLCJtYWMiOiJiMTljNTc4NWNiM2FjNzMyMjg5MmFjMTVlNTliNjJlOTg4Yjk2NTUwMDBmNzhkYTEyNGEyNmE5ODAwMmE5MmQ3IiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=laxalphaeurekaselectnet_session=eyJpdiI6IkQ1OVRxdTJmZnRPRmJ2K2UxNEQ3bXc9PSIsInZhbHVlIjoiTWVFcWp3ZDU1R21xUG9XWk1laXZ4NDZ1UkxYb3hMQ2NINjFzVE50YjU4dkNuNkh4V3o1NVlvcHh" ] "Set-Cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6ImVSem1TOENldjlZSi9TSysyUWZ2ekE9PSIsInZhbHVlIjoiclk4aGQyV05pTEVISHE3eXNqUG41UFZQNHBWVCtUVTB6U3lWOU5xWmlOU2c5SFNkQjJrdmQ5emFoZi9CTWpMUHgyb3dwREdwREV2bXduRzFxdEZlTzVNbjhSTm9lbldIaU9uRk04U2pzNG9OUGowZndZcjVaMDFLM0l1bWkwRWsiLCJtYWMiOiJjNTllNjZjMDY3ZWJmZjgwNDMyN2NlNDc1MjA2ODE2ZWM2OGUzNGIzNTkyNTJkYTAwOThjYzkyYWQ3ZmZkMzI0IiwidGFnIjoiIn0%3D; expires=Sat, 22-Feb-2025 06:11:45 GMT; path=/; secureXSRF-TOKEN=eyJpdiI6ImVSem1TOENldjlZSi9TSysyUWZ2ekE9PSIsInZhbHVlIjoiclk4aGQyV05pTEVISHE3eXNqUG41UFZQNHBWVCtUVTB6U3lWOU5xWmlOU2c5SFNkQjJrdmQ5emFoZi9CTWpMUHgyb3dwR" 1 => "alphaeurekaselectnet_session=eyJpdiI6IkQ1OVRxdTJmZnRPRmJ2K2UxNEQ3bXc9PSIsInZhbHVlIjoiTWVFcWp3ZDU1R21xUG9XWk1laXZ4NDZ1UkxYb3hMQ2NINjFzVE50YjU4dkNuNkh4V3o1NVlvcHhaSGRDWU05YXNvNDlkWTIzMlJzSFJYaTVGdHA3VXdDdmFwMWV3OG16STZ4WW5tM0FLWUZGcGZoOTdXWUZ3UUYrNk5WZDl1YWgiLCJtYWMiOiJiMTljNTc4NWNiM2FjNzMyMjg5MmFjMTVlNTliNjJlOTg4Yjk2NTUwMDBmNzhkYTEyNGEyNmE5ODAwMmE5MmQ3IiwidGFnIjoiIn0%3D; path=/; secure; httponlyalphaeurekaselectnet_session=eyJpdiI6IkQ1OVRxdTJmZnRPRmJ2K2UxNEQ3bXc9PSIsInZhbHVlIjoiTWVFcWp3ZDU1R21xUG9XWk1laXZ4NDZ1UkxYb3hMQ2NINjFzVE50YjU4dkNuNkh4V3o1NVlvcHh" ] ]
        session_attributes
        0 of 0
        array:5 [ "_token" => "bSUpWTLBmXtrx85ab5LhX2t7EgWwc2wnj6eqTU4f" "uc_cart_id" => "0a7796c4509cb24f024d6c472bc0d981" "_previous" => array:1 [ "url" => "http://alpha.eurekaselect.com/article/109125/cn" ] "_flash" => array:2 [ "old" => [] "new" => [] ] "PHPDEBUGBAR_STACK_DATA" => [] ]
        ClearShow all
        Date ↕MethodURLData
        #12025-02-19 18:11:45GET/article/109125/cn314413